Vitiligo Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Clinuvel Pharma, Bioniz Therapeutics, TAGCyx Biotech, Temprian Therapeutics, Aclaris

Vitiligo Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Clinuvel Pharma, Bioniz Therapeutics, TAGCyx Biotech, Temprian Therapeutics, Aclaris
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Vitiligo pipeline constitutes 22+ key companies continuously working towards developing 22+ Vitiligo treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Vitiligo Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Vitiligo Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vitiligo Market.


Some of the key takeaways from the Vitiligo Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Vitiligo treatment therapies with a considerable amount of success over the years. 
  • Vitiligo companies working in the treatment market are Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, Dermira, Arcutis Biotherapeutics, and others, are developing therapies for the Vitiligo treatment 
  • Emerging Vitiligo therapies in the different phases of clinical trials are- Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, QLT-450, PF-06651600, ARQ-252, and others are expected to have a significant impact on the Vitiligo market in the coming years.   
  • In October 2021, Incyte announced the validation of the European Marketing Authorization Application(MAA) for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults(age >12 years) with non-segmental vitiligo with facial involvement.
  • In December 2021, the US. Food and Drug Administration (FDA) accepted for Priority Review thesupplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAKinhibitor, as a potential treatment for adolescents and adults (age ≥12 years) with vitiligo.
  • AnaptysBio with its ANB030 (Anti-PD-1 Agonist) program is moving into a healthy volunteer Phase 1 trial, with top-line data anticipated in mid-2021. If all goes well, Phase 2 clinical trials in alopecia areata and vitiligo are scheduled for Q4 2021.


Vitiligo Overview

A complicated pigment disorder called vitiligo affects the skin, hair, and sporadically the mucous membranes. Although vitiligo can affect any area of skin, it most frequently affects the hands, neck, and face. Clinically, vitiligo manifests as milk-white, irregularly shaped oval patches of skin that start out small and then gradually get bigger.


Get a Free Sample PDF Report to know more about Vitiligo Pipeline Therapeutic Assessment-


Emerging Vitiligo Drugs Under Different Phases of Clinical Development Include:

  • Phimelanotide: Clinuvel Pharmaceuticals
  • BNZ-1: Bioniz Therapeutics
  • TAGX-0003: TAGCyx Biotechnologies
  • TT-01: Temprian Therapeutics
  • ATI-1777: Aclaris Therapeutics
  • AC-1101: TWi Biotechnology
  • Cerdulatinib: Dermavant Sciences
  • AMG 714: Amgen
  • Ritlecitinib: Pfizer
  • Ruxolitinib: Incyte Corporation
  • QLT-450: Dermira
  • AMG-714: Amgen
  • PF-06651600: Pfizer
  • ARQ-252: Arcutis Biotherapeutics


Vitiligo Route of Administration

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Vitiligo Molecule Type

Vitiligo Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type


Vitiligo Pipeline Therapeutics Assessment

  • Vitiligo Assessment by Product Type
  • Vitiligo By Stage and Product Type
  • Vitiligo Assessment by Route of Administration
  • Vitiligo By Stage and Route of Administration
  • Vitiligo Assessment by Molecule Type
  • Vitiligo by Stage and Molecule Type


DelveInsight’s Vitiligo Report covers around 22+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Vitiligo product details are provided in the report. Download the Vitiligo pipeline report to learn more about the emerging Vitiligo therapies


Some of the key companies in the Vitiligo Therapeutics Market include:

Key companies developing therapies for Vitiligo are – Bausch Health Companies Inc., Strides Pharma Science Limited, Mylan N.V., Arcutis Biotherapeutics, Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd, Panacea Biotec Ltd, Glenmark Pharmaceuticals Ltd, Belcher Pharmaceuticals, LCC, Pfizer Inc., Celgene Corporation, clinuvel pharmaceuticals ltd., and others.


Vitiligo Pipeline Analysis:

The Vitiligo pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
  • Vitiligo key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Vitiligo drugs and therapies


Vitiligo Pipeline Market Drivers

  • Increasing awareness, demand of novel therapies, large patient pool and better healthcare infrastructure are some of the important factors that are fueling the Vitiligo Market.


Vitiligo Pipeline Market Barriers

  • However, patient compliance, chronic nature of disease and long term therapy, lack of adequate financial assistance & stringent regulatory procedure and other factors are creating obstacles in the Vitiligo Market growth.


Scope of Vitiligo Pipeline Drug Insight    

  • Coverage: Global
  • Key Vitiligo Companies: , and others
  • Key Vitiligo Therapies: Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, QLT-450, PF-06651600, ARQ-252, and others
  • Vitiligo Therapeutic Assessment: Vitiligo current marketed and Vitiligo emerging therapies
  • Vitiligo Market Dynamics: Vitiligo market drivers and Vitiligo market barriers 


Request for Sample PDF Report for Vitiligo Pipeline Assessment and clinical trials


Table of Contents

1. Vitiligo Report Introduction

2. Vitiligo Executive Summary

3. Vitiligo Overview

4. Vitiligo- Analytical Perspective In-depth Commercial Assessment

5. Vitiligo Pipeline Therapeutics

6. Vitiligo Late Stage Products (Phase II/III)

7. Vitiligo Mid Stage Products (Phase II)

8. Vitiligo Early Stage Products (Phase I)

9. Vitiligo Preclinical Stage Products

10. Vitiligo Therapeutics Assessment

11. Vitiligo Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Vitiligo Key Companies

14. Vitiligo Key Products

15. Vitiligo Unmet Needs

16 . Vitiligo Market Drivers and Barriers

17. Vitiligo Future Perspectives and Conclusion

18. Vitiligo Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States